Kenny Simmen

1.1k total citations
8 papers, 327 citations indexed

About

Kenny Simmen is a scholar working on Infectious Diseases, Hepatology and Molecular Biology. According to data from OpenAlex, Kenny Simmen has authored 8 papers receiving a total of 327 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Infectious Diseases, 5 papers in Hepatology and 3 papers in Molecular Biology. Recurrent topics in Kenny Simmen's work include Hepatitis C virus research (5 papers), HIV/AIDS drug development and treatment (4 papers) and Biochemical and Molecular Research (2 papers). Kenny Simmen is often cited by papers focused on Hepatitis C virus research (5 papers), HIV/AIDS drug development and treatment (4 papers) and Biochemical and Molecular Research (2 papers). Kenny Simmen collaborates with scholars based in Belgium, United States and Sweden. Kenny Simmen's co-authors include Pierre Raboisson, Oliver Lenz, Maxwell D. Cummings, Sandrine Vendeville, Bertil Samuelsson, Åsa Rosenquist, Magnus Nilsson, András Horváth, Herman de Kock and Per-Ola Johansson and has published in prestigious journals such as Gastroenterology, PLoS ONE and Journal of Medicinal Chemistry.

In The Last Decade

Kenny Simmen

8 papers receiving 322 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kenny Simmen Belgium 7 128 121 99 99 96 8 327
Satoru Noji Japan 6 115 0.9× 146 1.2× 68 0.7× 79 0.8× 56 0.6× 8 385
Sandrine Vendeville France 11 135 1.1× 174 1.4× 184 1.9× 144 1.5× 195 2.0× 15 519
John P. Maxwell United States 8 212 1.7× 79 0.7× 127 1.3× 107 1.1× 154 1.6× 23 409
Francisco X. Talamás United States 12 66 0.5× 172 1.4× 152 1.5× 77 0.8× 59 0.6× 19 408
Dawn D. Parker United States 13 145 1.1× 137 1.1× 154 1.6× 203 2.1× 134 1.4× 22 498
Per-Ola Johansson Sweden 6 88 0.7× 100 0.8× 109 1.1× 66 0.7× 49 0.5× 7 280
Michael G. Darcy United States 12 82 0.6× 222 1.8× 135 1.4× 60 0.6× 56 0.6× 13 524
Naoki Ogura Japan 9 117 0.9× 187 1.5× 91 0.9× 45 0.5× 117 1.2× 19 374
Frédéric Delouvroy Sweden 4 141 1.1× 44 0.4× 50 0.5× 74 0.7× 97 1.0× 5 210
John Pichardo United States 15 205 1.6× 153 1.3× 163 1.6× 146 1.5× 120 1.3× 30 458

Countries citing papers authored by Kenny Simmen

Since Specialization
Citations

This map shows the geographic impact of Kenny Simmen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenny Simmen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenny Simmen more than expected).

Fields of papers citing papers by Kenny Simmen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenny Simmen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenny Simmen. The network helps show where Kenny Simmen may publish in the future.

Co-authorship network of co-authors of Kenny Simmen

This figure shows the co-authorship network connecting the top 25 collaborators of Kenny Simmen. A scholar is included among the top collaborators of Kenny Simmen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenny Simmen. Kenny Simmen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Amssoms, Katie, Ellen Van Gulck, Wouter L.J. Hinrichs, et al.. (2018). Ovalbumin-containing core-shell implants suitable to obtain a delayed IgG1 antibody response in support of a biphasic pulsatile release profile in mice. PLoS ONE. 13(8). e0202961–e0202961. 9 indexed citations
3.
Rosenquist, Åsa, Bertil Samuelsson, Per-Ola Johansson, et al.. (2014). Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor. Journal of Medicinal Chemistry. 57(5). 1673–1693. 158 indexed citations
4.
Ivens, Tania, et al.. (2013). Cell-Based Antiviral Assays for Screening and Profiling Inhibitors Against Dengue Virus. Methods in molecular biology. 1030. 185–194. 3 indexed citations
5.
Jonckers, Tim H. M., Koen Vandyck, Lili Hu, et al.. (2013). Nucleotide Prodrugs of 2′-Deoxy-2′-spirooxetane Ribonucleosides as Novel Inhibitors of the HCV NS5B Polymerase. Journal of Medicinal Chemistry. 57(5). 1836–1844. 33 indexed citations
6.
Rouan, M.C., Tom Gevers, Dirk Roymans, et al.. (2010). Pharmacokinetics-Pharmacodynamics of a Respiratory Syncytial Virus Fusion Inhibitor in the Cotton Rat Model. Antimicrobial Agents and Chemotherapy. 54(11). 4534–4539. 17 indexed citations
7.
Vandyck, Koen, Maxwell D. Cummings, Origène Nyanguile, et al.. (2009). Structure-Based Design of a Benzodiazepine Scaffold Yields a Potent Allosteric Inhibitor of Hepatitis C NS5B RNA Polymerase. Journal of Medicinal Chemistry. 52(14). 4099–4102. 50 indexed citations
8.
Liang, Yuqiong, Hisashi Ishida, Oliver Lenz, et al.. (2008). Antiviral Suppression vs Restoration of RIG-I Signaling by Hepatitis C Protease and Polymerase Inhibitors. Gastroenterology. 135(5). 1710–1718.e2. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026